![The Rise Of Vegan Marijuana Gummies: Benefits And Options [4yTnldRQWZS]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-5469039.jpg?resize=150%2C150&ssl=1 "The Rise Of Vegan Marijuana Gummies: Benefits And Options 24")
Maryland Just Adopted New Cannabis Packaging and Product Rules, and They Take Effect Tomorrow
A new oral mucosal product category and a loosened packaging standard land in the same rule package. Both change what a Maryland patient sees on a shelf, and one of them changes how fast a dose arrives.
Maryland’s cannabis regulators took comment on a package of rule changes through late July, adopted them on August 13, and published the final notice on September 4. The amendments take effect September 14, 2026. They define what counts as a medical claim, drop the plain packaging requirement while tightening restrictions on packaging that appeals to children, and create a new sublingual pouch product category.
This is a regulatory story with two clinically relevant pieces. The first is a new product category: sublingual pouches, defined in Maryland’s regulation as a permeable sachet containing cannabis concentrate intended to dissolve in the mouth and be absorbed buccally or sublingually. The second is a packaging standard that moves from plain and opaque to opaque, paired with an expanded list of design elements that may not appear on a package.
The Maryland Cannabis Administration adopted the amendments on August 13, 2026. The Notice of Final Action appeared in the September 4, 2026 Maryland Register, and the rules take effect September 14, 2026. The proposal had been published at 53:13 Md. R. 610 to 613 on June 26, 2026, with comments accepted through July 27. The comment window closed weeks ago.
| Audience | Patients, caregivers, clinicians, and Maryland consumers |
| Primary Topic | Maryland’s adopted 2026 amendments to COMAR 14.17 covering packaging, medical claims, and sublingual pouches |
| Source | Read the full source |
Patients do not read the Code of Maryland Regulations. They read packages. When a state redefines what a package may say and adds a product category with a different absorption route, the change reaches the exam room as a question about what something is and how fast it works.
The claims definition is the quiet one. Maryland now defines a medical and therapeutic claim as any representation that cannabis will relieve, treat, diagnose, or prevent a health condition or any other ailment. That is a broad definition, and it governs what a licensee may print next to a product a patient is deciding whether to buy.
The Maryland Cannabis Administration proposed amendments to seven chapters of COMAR 14.17 in the June 26, 2026 Maryland Register, at 53:13 Md. R. 610 to 613, and accepted public comment through July 27, 2026. The agency adopted the package on August 13, 2026. The Notice of Final Action ran in the September 4, 2026 issue, 53:18, and the amendments take effect September 14, 2026.
The chapters touched are 14.17.01 Definitions, 14.17.05 Application Process and Issuance of Licenses, 14.17.10 Cannabis Grower Operations, 14.17.12 Cannabis Dispensary Operations, 14.17.13 Cannabis Products, 14.17.18 Finished Product Packaging, and 14.17.22 Hearing Procedures.
The agency adopted with what the notice calls nonsubstantive changes: a clarified definition of sublingual pouch, clarified documentation of good faith effort regarding a premises, terminology aligned with terms already defined in regulation, and a renumbering correction. Anyone who read the proposal in June is reading substantially the same rules today.
Maryland’s regulation defines a sublingual pouch as a permeable sachet containing cannabis concentrate intended to be dissolved in the mouth and absorbed buccally or sublingually. The regulatory text sets a standard limit of up to 2.5 milligrams of THC per serving and 25 milligrams per package, with a higher tier of up to 10 milligrams per serving and 100 milligrams per package for unflavored products or flavors the administration approves. A pouch may contain a cannabis concentrate and fillers, and sales are restricted by age.
The pharmacology is the part worth pausing on. Buccal and sublingual absorption bypasses some of the first pass hepatic metabolism that converts oral THC into 11-hydroxy-THC, so the onset is generally faster than a swallowed edible and the metabolite profile differs. In practice absorption from an oral mucosal product is mixed, because saliva carries a portion of the dose down the throat where it behaves like an edible.
The practical counseling point: a pouch is not a faster gummy and it is not an inhaled product. Onset tends to sit between the two, effects can continue arriving after a patient removes the pouch, and the swallowed fraction means a delayed second wave is normal rather than a sign the first dose failed.
The format also borrows heavily from nicotine pouches, which is a consumer familiarity advantage and a household safety liability at the same time.
The prior standard required cannabis packaging to be plain and opaque. The adopted amendment strikes plain and keeps opaque. In exchange, the prohibition on youth-appealing design expands from a general bar on images to a list: images, graphics, font styles, features, or likenesses popularly used to advertise to children, including cartoons, animals, neon colors, celebrities, mascots, and phrases.
Whether that trade improves or weakens youth protection is a genuinely open question, and reasonable people in public health will disagree. Plain packaging has evidence behind it in tobacco. A branded package that is prohibited from using cartoons, mascots, and neon is not the same as a plain one, and the enforcement burden shifts from a bright line to a judgment call about what a font style signals.
What this does not change is the reason packaging rules exist at all. Maryland cannabis products still need to be stored where children cannot reach them. A more attractive package sitting on a counter is not a safer package.
The claims language also tightened. Where the rule previously barred claims regarding health or physical benefits to the consumer, it now bars medical or therapeutic claims, with 14.17.01 defining that term as any representation that cannabis will relieve, treat, diagnose, or prevent health conditions or any other ailment.
Beyond packaging and products, the amendments reach operations. Conditional licensees may now receive up to two extensions of as long as six months each on a showing of good faith effort, replacing a single extension. Growers face corrective and preventive action requirements after repeated testing failures, including contamination investigation and decontamination procedures, and must maintain minimum labor standards and policies addressing discrimination, harassment, and retaliation.
Micro dispensaries may be required to provide certain health and safety materials at the point of sale, including with delivery orders. That is a small provision with outsized patient-facing potential, because for many buyers the point of sale is the only moment any health information is offered at all.
The grower testing provisions deserve more attention than they will get. Repeated laboratory failures are the upstream cause of most contaminant problems that reach a patient, and a corrective action requirement is a more meaningful consumer protection than a font rule.
Nothing in this package changes patient eligibility, purchase limits, or who may certify a patient. If your access to medical cannabis in Maryland worked last week, it works this week.
What changes is the shelf. Expect branded packaging to appear more varied, expect sublingual pouches to show up as a new category, and expect product descriptions to avoid explicitly medical language because the state has now defined that language. A product that stops claiming to treat something has not become less effective. It has become more carefully worded.
For anyone trying a sublingual pouch for the first time, the sensible approach is a single low-dose pouch, no redosing for at least two hours, and no driving until the pattern of onset and duration is known. Keep the product in its child-resistant packaging, because a pouch is small, portable, and looks like something adults use casually in public.
| Agency | Maryland Cannabis Administration |
| Regulations Amended | COMAR 14.17.01, .05, .10, .12, .13, .18, and .22 |
| Proposed | 53:13 Md. R. 610 to 613, June 26, 2026 |
| Comment Period | Closed July 27, 2026 |
| Adopted | August 13, 2026, with nonsubstantive changes certified by the Attorney General |
| Final Notice Published | Maryland Register 53:18, September 4, 2026 |
| Effective Date | September 14, 2026 |
| New Product Category | Sublingual pouch, defined as a permeable sachet of cannabis concentrate absorbed buccally or sublingually |
| Pouch Limits | Up to 2.5 mg THC per serving and 25 mg per package; up to 10 mg per serving and 100 mg per package for unflavored or approved flavors |
| Packaging Change | Plain and opaque becomes opaque; youth-appeal prohibitions expanded to cartoons, animals, neon colors, celebrities, mascots, and phrases |
| Claims Definition | A medical and therapeutic claim is any representation that cannabis will relieve, treat, diagnose, or prevent health conditions or any other ailment |
This is documentary rather than empirical, and the documents are unusually clean. The proposal, the comment deadline, the adoption date, the register citation, and the effective date all appear in the Maryland Register, and the regulatory text is posted by the agency. There is nothing here that requires trusting a summary.
What no document supplies is outcome. Maryland has not published, and will not publish for years, any evidence on whether the packaging change affects youth exposure or whether the claims definition changes how patients interpret products. Those remain open empirical questions dressed as settled policy.
The agency’s own framing said the proposal was not expected to alter existing processes or create operational impact. That is a reasonable description of the licensing and hearing provisions and an odd description of a rule that creates a new product category and rewrites the packaging standard. Read that sentence as regulatory boilerplate, not as an impact assessment.
The packaging trade deserves scrutiny from both directions. Dropping plain packaging in exchange for a longer list of prohibited design elements is defensible, but the evidence base for plain packaging in tobacco is stronger than the evidence base for enumerated design bans in cannabis. Maryland has chosen the less tested approach.
Adding sublingual pouches to a product schedule is a regulatory act, not a clinical validation. No trial supports the category, and the naming of a route in a state regulation says nothing about whether it works better than any other route for any condition.
The rules also do not show how they will be enforced. A definition of medical and therapeutic claim is only as strong as the inspection and penalty practice behind it, and Maryland has published no enforcement record for a rule that takes effect tomorrow.
State cannabis programs mature through rulemaking rather than through headline legislation, and this is what that looks like. Definitions, product schedules, packaging limits, and point of sale materials are where a market’s assumptions get encoded, and they move with far less public attention than a legalization vote.
Maryland’s youth-appeal language also runs parallel to what other states are doing. California signed Assembly Bill 2249 on August 31, 2026 restricting cannabis packaging, labeling, and advertising that appeal to children. Two states arriving at similar restrictions within a fortnight suggests a converging regulatory consensus about where the risk sits.
The piece of this I care about clinically is the pouch. A patient who has used edibles for two years and switches to a buccal product will encounter a different onset curve and will probably redose too early at least once. That is a conversation worth having before it happens rather than after.
On packaging, I am less certain than the people on either side of it. Plain packaging has real evidence behind it in tobacco, and I am not persuaded that a list of prohibited cartoons is equivalent. But a rule that bans mascots and neon while allowing a legible brand is not obviously worse than one that made every package look interchangeable and therefore hard to identify in a recall.
Maryland’s amended cannabis rules are final and take effect September 14, 2026. The comment period closed in July. Expect branded packaging without cartoons, mascots, or neon, expect more carefully worded product descriptions, and expect sublingual pouches on shelves. Counsel patients trying a pouch that onset sits between an edible and an inhaled product, that a swallowed fraction produces a delayed second wave, and that redosing inside two hours is the common mistake.
Carry forward the dates and the substance: adopted August 13, effective September 14, plain packaging removed, youth-appeal restrictions expanded, sublingual pouches added, medical claims defined. Do not carry forward any sense that naming a product category is a clinical endorsement of it.
How to read a state rule package without mistaking definition for validation
Maryland’s 2026 Cannabis Rule Package, Seen From Eight Angles
One rulemaking, a new product route, and a packaging standard that moved in two directions at once.
Your access did not change; the shelf did
This package does not touch eligibility, certification, or purchase limits. What changes is what products exist and how they are packaged and described. Branded packaging returns within limits, and a new sublingual pouch category appears.
If a product you have used stops describing what it treats, that is the new claims definition at work rather than a reformulation. The contents did not change because the wording did.
The pouch is the part to counsel on
Buccal and sublingual delivery partially bypasses first pass metabolism, so onset is generally faster than a swallowed edible while a swallowed fraction still produces a later, edible-like wave. Patients switching from gummies will read the early onset as the whole effect and redose.
Set the expectation explicitly: one low-dose pouch, no second dose for at least two hours, no driving until the individual pattern is known.
The agency called this operationally neutral
The Maryland Cannabis Administration described the proposal as not altering existing processes and not anticipated to have operational impact. That is a fair description of the hearing procedure and licensing extension provisions and a strange one for a rule creating a product category and rewriting packaging.
Treat that language as procedural boilerplate required by the rulemaking process rather than as an assessment anyone should rely on.
Dropping plain packaging is the contested choice
Plain packaging has a real evidence base in tobacco control. An enumerated list of prohibited design elements does not, and it converts a bright line into a case by case judgment about whether a font or a color reads as child-directed.
There is a counterargument worth stating: uniform packaging makes products harder to distinguish in a recall or a poisoning call. Neither position has Maryland-specific data behind it yet.
Rulemaking is how these programs actually change
Maryland legalized adult use in 2023 and has been tuning the regulatory detail since. Product schedules, packaging standards, and claims definitions are where the real decisions accumulate, and they move through the Maryland Register rather than through the legislature.
Each of these amendments has a proposal, a comment period, and a final notice with citations. That trail is public and worth following if the market matters to your patients.
First use of a sublingual pouch
Start with the lowest available strength, which under the adopted limits will be a 2.5 milligram serving for flavored products. Place the pouch, leave it in place for the time the manufacturer specifies, and note when effects begin and when they peak.
Do not redose for at least two hours. Keep the product in child-resistant packaging and out of bags and pockets where a child or an unaware adult could mistake it for a nicotine pouch.
Enforcement is the open variable
A claims definition is only as meaningful as the inspections and penalties behind it. Whether Maryland cites licensees for medical or therapeutic claims, and how it draws the line on youth-appealing design, will determine whether these rules change anything patients notice.
Watch the administration’s enforcement actions over the next two to three quarters rather than the rule text.
Two states converging on youth appeal
Maryland’s expanded prohibition on cartoons, animals, neon colors, celebrities, mascots, and phrases lands two weeks after California signed Assembly Bill 2249 restricting cannabis packaging, labeling, and advertising that appeal to children.
Converging state rules like these tend to become the de facto national standard for multistate manufacturers, because it is cheaper to print one compliant package than several.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Are Maryland’s proposed cannabis rule changes final?
Yes. The Maryland Cannabis Administration adopted the amendments on August 13, 2026, the Notice of Final Action appeared in the September 4, 2026 Maryland Register, and the rules take effect September 14, 2026. The comment period closed on July 27, 2026. The agency adopted the package with nonsubstantive changes, including a clarified definition of sublingual pouch and a renumbering correction.
What is a sublingual pouch under Maryland’s new rules?
Maryland defines it as a permeable sachet containing cannabis concentrate intended to dissolve in the mouth and be absorbed buccally or sublingually. The regulation allows up to 2.5 milligrams of THC per serving and 25 milligrams per package, with a higher tier of up to 10 milligrams per serving and 100 milligrams per package for unflavored products or flavors the administration approves.
Did Maryland remove its plain packaging requirement?
Yes. The packaging standard changed from plain and opaque to opaque, so branded design is permitted again within limits. In exchange, the prohibition on youth-appealing packaging expanded from a general bar on images to a specific list covering cartoons, animals, neon colors, celebrities, mascots, and phrases popularly used to advertise to children.
What counts as a medical claim under the new Maryland rules?
The amended definitions chapter defines a medical and therapeutic claim as any representation that indicates cannabis will relieve, treat, diagnose, or prevent health conditions or any other ailment. That is a broad standard, and the packaging chapter now prohibits medical or therapeutic claims rather than the narrower prior language about health or physical benefits to the consumer.
How fast does a sublingual pouch work compared with an edible?
Generally faster, but not cleanly so. Buccal and sublingual absorption partially bypasses first pass liver metabolism, which shortens onset relative to a swallowed edible. A portion of every dose is still swallowed in saliva and behaves like an edible, producing a later second wave. Patients who judge the full effect from the first thirty minutes tend to redose too early.
Do these rules change who can buy medical cannabis in Maryland?
No. The adopted package addresses definitions, licensing procedure, grower operations, dispensary operations, product categories, finished product packaging, and hearing procedures. It does not alter patient eligibility, certification requirements, or purchase limits. If your access worked before September 14, 2026, it works after.
What else did the package change besides packaging and products?
Conditional licensees may receive up to two extensions of as long as six months each on a showing of good faith effort. Growers with repeated testing failures face corrective and preventive action requirements including contamination investigation and decontamination. Growers must maintain minimum labor standards. Regulators may require micro dispensaries to provide health and safety materials at the point of sale, including with delivery orders.
Does a new product category mean the product has been clinically validated?
No. Adding sublingual pouches to a state product schedule is a regulatory decision about what may be manufactured and sold. It reflects no trial evidence about efficacy for any condition and no comparison against other routes. Judge a pouch the way you would judge any cannabis product: by its labeled milligrams, its batch testing, and your own carefully titrated response.
